ADVM Rasio cepet Adverum Biotechnologies Inc.

Adverum Biotechnologies focuses on implementing innovative gene therapy methods for ophthalmological pathologies via the drug Ixo-vec to capture market share. Their key advantage is the creation of IXIQ, which eliminates the need for regular injections for patients, radically improving the quality of life for those with macular degeneration. The current metric is 0.65. The stock's price history reflects the business dynamics within the wet AMD therapy ecosystem under strict FDA supervision.

The quick ratio measures a business's ability to instantaneously settle short-term obligations using only cash and accounts receivable, excluding illiquid inventories. For Adverum Biotechnologies (ADVM), whose sales depend on regulatory decisions within the gene therapy sector, current quick liquidity serves as an indicator of financial autonomy and protection against cash flow gaps while awaiting market entry.